Related Experiment Video

Updated: Mar 28, 2026

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

9.2K

MTDH is an oncogene in multiple myeloma, which is suppressed by Bortezomib treatment

Chunyan Gu1,2,3, Lang Feng4,5, Hailin Peng6

  • 1Department of Pathology, Nanjing Medical University, 210029, Nanjing, China.

Oncotarget
|December 20, 2015
PubMed

Insights

Metadherin (MTDH) is an oncogene in multiple myeloma (MM), promoting cancer growth. Bortezomib treatment suppresses MTDH, offering a potential therapeutic strategy for MM patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Genetics

Background:

  • Metadherin (MTDH) is a known oncogene in various cancers, but its role in multiple myeloma (MM) remains uncharacterized.
  • Understanding MTDH's function in MM is crucial for developing targeted therapies.

Purpose of the Study:

  • To investigate the role of Metadherin (MTDH) as an oncogene in multiple myeloma (MM).
  • To explore the correlation between MTDH expression, MM subgroups, patient outcomes, and response to Bortezomib treatment.

Main Methods:

  • Analysis of MTDH mRNA levels and chromosomal gain in MM cells.
  • Correlation studies between MTDH expression and patient survival in different cohorts (TT2, TT3).
  • In vitro and in vivo experiments involving MTDH knockdown using shRNA and Bortezomib treatment.

Main Results:

  • MTDH expression is elevated in MM cells, associated with chromosomal gain, and higher in the high-risk MMSET translocation (MS) subgroup.
  • High MTDH expression correlated with poor survival in the TT2 cohort, but favorable survival in the TT3 cohort, where Bortezomib treatment was prevalent.
  • MTDH knockdown induced apoptosis and inhibited MM cell growth in vitro and in vivo.
  • Bortezomib suppressed MTDH expression at both pre- and post-transcriptional levels.
  • MTDH was identified as a transcriptional target of the MMSET/NFκB/MYC signaling pathway, which is inhibited by Bortezomib.

Conclusions:

  • MTDH functions as an oncogene in multiple myeloma.
  • MTDH expression levels and their prognostic significance are influenced by treatment context, particularly Bortezomib.
  • Bortezomib exerts its anti-myeloma effects, in part, by downregulating MTDH expression and inhibiting the MMSET/NFκB/MYC pathway.
Keywords:
BortezomibMMSET (WHSC1)metadherin (MTDH)multiple myelomaoncogene

More Related Videos

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.6K
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

14.0K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.7K